= Fully recruited
= Recruiting
= Not yet recruiting
= Enrolling by invitation
This is a Phase 3, double-blind, placebo-controlled study with the primary objective of evaluating the efficacy of a single IV infusion of SGT-003 in pediatric ambulant male participants with DMD. The secondary objectives include the evaluation of additional efficacy and safety outcomes. The study will be divided into 2 parts. Approximately 80 participants will be enrolled in the study. Participants will be randomized 1:1 to either SGT-003 in Part 1 followed by placebo in Part 2 or to placebo in Part 1 followed by SGT-003 in Part 2. Participants will continue to be monitored in long term follow up (LTFU) for at least 5 years from their SGT-003 dosing date. |
This is a Phase 3, double-blind, placebo-controlled study with the primary objective of evaluating the efficacy of a single IV infusion of SGT-003 in pediatric ambulant male participants with DMD. The secondary objectives include the evaluation of additional efficacy and safety outcomes. The study will be divided into 2 parts. Approximately 80 participants will be enrolled in the study. Participants will be randomized 1:1 to either SGT-003 in Part 1 followed by placebo in Part 2 or to placebo in Part 1 followed by SGT-003 in Part 2. Participants will continue to be monitored in long term follow up (LTFU) for at least 5 years from their SGT-003 dosing date. Functional efficacy assessments will be performed at Screening/Baseline, Day 90, Day 180, Day 360, and Day 540. These assessments will include evaluations of motor function (timed function tests [time to rise from supine, 10-meter walk/run, 4-stair climb], North Star Ambulatory Assessment [NSAA], video assessment, and activity monitoring by wearable device (stride velocity 95th centile [SV95C]), pulmonary function (% predicted forced vital capacity [FVC], peak expiratory flow [PEF], forced expiratory volume in 1 second [FEV1]), and patient-reported outcome (PRO) measures (Pediatric Outcomes Data Collection Instrument [PODCI]). Individual outcome assessments will be evaluated at each timepoint, and change from baseline will be calculated for interpretation of differences over time. In addition, the first 20 participants enrolled in the study at investigative sites capable of performing muscle biopsies will have muscle biopsies performed at the Screening Visit and at the Part 1 Day 90 Visit. Investigative sites able to conduct biopsies will continue enrolling to ensure that approximately 20 participants will have biopsies performed. |
|
|
|
|
1. Participant 7 to <12 years of age. 2. Participant is ambulatory. Ambulatory is defined as “being able to walk without the use of an assistive device.” 3. Established clinical diagnosis of DMD and documented dystrophin gene mutation predictive of DMD phenotype. 4. Negative for antibodies against AAV9. 5. A stable daily oral regimen of at least 0.5 mg/kg/day prednisone or 0.75 mg/kg/day deflazacort for at least 6 months prior to entering the study, allowing for weight-based dose modifications in accordance with clinical practice. 6. 10-meter walk/run time <10 seconds. 7. Time to rise from supine <7 seconds and not faster than 3 seconds or faster than the 90th percentile for age. 8. Participant has bodyweight ≤50 kg. 9. Participant is genetically male. 10. Participant is able to understand and comply with all study procedures as appropriate by age and has a parent(s) or legal guardian(s) (i.e., legally authorized representative [LAR]) who is (are) able to understand and comply with the study procedure requirements. Be willing to provide informed assent and have an LAR(s) who is (are) willing to provide written informed consent for the participant to participate in the study. 11. If participant is of reproductive potential, participant and partner of childbearing potential are willing to use 2 highly effective forms of contraception for 12 months following study drug administration. |
a. Clinical History in the opinion of the primary investigator
b. Ejection fraction [EF]
c. EF <50-55% and the presence of late gadolinium enhancement by cardiac MRI that is determined to be clinically significant or includes 3 or more segments